Key result
ART-treated HIV infection is linked to significantly lower heart rate variability compared to uninfected controls.
Why the study?
HIV infection treated with ART has transformed HIV into a chronic disease with emerging complications including cardiovascular diseases, but the association between HRV and HIV treated with ART in rural African populations is unclear.
Does HIV infection treated with ART reduce heart rate variability compared to HIV-uninfected individuals in a rural African population?
Cross-Sectional (n=325)
Does HIV infection treated with ART reduce heart rate variability compared to HIV-uninfected individuals in a rural African population?
Effect estimate: coefficient -0.16 for log RMSSD and -0.61 for log pNN50
HIV-infected patients on ART have lower heart rate variability despite having fewer conventional cardiovascular risk factors, suggesting an increased risk for cardiovascular disease.
May signal elevated CV risk in treated HIV; hypothesis-generating and requires prospective validation in similar cohorts.
Background: Antiretroviral therapy (ART) transformed human immunodeficiency virus (HIV) infection into a chronic disease. Possible HIV-associated complications have emerged including cardiovascular diseases (CVD). Objectives: This study aims to determine the heart rate variability (HRV) distribution and association between HRV and HIV treated with ART in a rural African population. Methods: This cross-sectional study included 325 participants of the Ndlovu Cohort Study, South Africa. HRV was measured using a standardized five-minute resting ECG and assessed by the standard deviation of normal RR intervals (SDNN), root of mean squares of successive RR differences (RMSSD), percentage of RR intervals greater than 50 milliseconds different from its predecessor (pNN50), total-, low- and high-frequency power. CVD risk factors were assessed using measurements (blood pressure, anthropometry, cholesterol) and questionnaires (e.g. socio-demographics, alcohol, smoking, physical activity, age, diabetes). We used a Wilcoxon rank test to assess differences in medians between HIV-infected and HIV-uninfected participants and multivariable linear regression to investigate associations between HRV and HIV treated with ART. Conclusions: Of the participants, 196 (61.4%) were HIV-infected treated with ART and 123 (38.6%) were HIV-uninfected. HIV-infected consumed less alcohol, 52% versus 35%, smoked less, were less physically active, more often attained lower education, 26% versus 14%, and had lower systolic blood pressure, 134 mmHg versus 140 mmHg, compared to HIV-uninfected. Medians of all HRV parameters were lower for HIV-infected participants. The model fully adjusted for CVD risk factors showed a significant inverse association between HIV treated with ART and log RMSSD (-0.16) and log pnn50 (-0.61). Although HIV-infected participants treated with ART presented with less CVD risk factors they had a lower HRV indicating an increased risk of CVD. Highlights: - African HIV-infected participants on ART had less conventional CVD risk factors than HIV-uninfected.- However, HIV-infected participants had lower HRV than HIV-uninfected participants.- Lower HRV of the HIV-infected participants indicates that they are at a higher risk for CVD.
No takes yet. Share an insight, caveat, or question.
Godijk et al. (2020) conducted a cross-sectional in HIV infection (n=325). HIV infection treated with ART vs. HIV-uninfected individuals was evaluated on Heart rate variability (log RMSSD and log pNN50) (coefficient -0.16 for log RMSSD and -0.61 for log pNN50). HIV infection treated with ART was significantly associated with lower heart rate variability (adjusted coefficient -0.16 for log RMSSD and -0.61 for log pNN50) compared to HIV-uninfected individuals.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: